LEAP IS DEVELOPING DRUGS TO CHANGE THE PRACTICE OF CANCER MEDICINE
DKN-01 is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein
DKN-01 is in clinical trials for gastroesophageal, hepatobiliary, gynecologic, and prostate cancer.
On November 9, 2018, Leap presented nonclinical and clinical data specifically from its study of DKN-01 in combination with paclitaxel in gastroesophageal cancer at the SITC 2018 meeting. Click here to view our poster.
On October 21, 2018, Leap presented nonclinical and clinical data from its ongoing study of DKN-01 in combination with KEYTRUDA (pembrolizumab) in patients with esophagogastric cancer at the ESMO 2018 meeting. Click here to view our poster.
TRX518 is a novel, humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody designed to enhance the immune system’s anti-tumor response as an immune checkpoint agonist
TRX518 is currently in repeat dose and combination clinical trials in solid tumor malignancies.
On December 14, 2018, Leap presented data from its TRX518 combination studies with gemcitabine, pembrolizumab or nivolumab in advanced solid tumors at the ESMO IO meeting. Click here to view our poster.
On November 9, 2018, MSKCC presented data from its study of TRX518 monotherapy in advanced solid tumors at the SITC 2018 meeting. Click here to view our poster.
47 Thorndike Street, Suite B1-1
Cambridge, MA 02141 USA